AIDS Drug Assistance Programs (ADAP) serve low-income, underinsured or uninsured HIV-positive patients in the United States and its territories. General eligibility requirements may include residency, clinical eligibility based on specific CD4 counts, and income. Specific eligibility criteria for each ADAP is determined by each individual state. Continue Reading
The number of patients sitting on AIDS Drug Assistance Programs (ADAP) wait lists, denied the life-saving treatment they need, have risen dramatically over the past two years. ADAPs are critical in providing HIV/AIDS treatment to low-income, uninsured, or underinsured patients within the United States and its territories. As noted in an earlier KEI blog, in January 2010, 361 individuals were on ADAP waitlists; that number grew to 7,873 across eleven states as of May 5, 2011 (a 2100% increase over less than sixteen months).
KEI research associate Paul Miano has written the following paper: Cancer: Approval, ownership, market structure, and placement on WHO Model Essential Medicines List, for 100 new molecular entities (NMEs) on the NCI alpha list of cancer drugs and vaccines. KEI Research Note 2011:1,
A full copy of the paper is available in PDF format here.
The following is from the introduction (sans footnotes, which are in the PDF version):
In the first seven months of 2011 (January 14 to July 20) , the US FDA has already approved 18 new molecular entity drugs. These are some notes on the approvals:
On 12 July 2011, the Medicines Patent Pool (MPP) and Gilead announced an agreement for Gilead to license patents for tenofovir (TDF), emtricitabine (FTC), elvitegravir (EVG), cobisistat (COBI) and a four drug combination of these drugs. KEI’s initial comments on the agreement are available here. Continue Reading
After ten years of deliberations, the 19th session (18-22 July 2011) of the WIPO Intergovernmental Committee on Intellectual Property and Genetic Resources, Traditional Knowledge and Folklore (IGC/GRTKF) submitted a Decision for approval to the WIPO General Assembly (26 September-5 October 2011) that could pave the way for the General Assembly in 2012 to convene a Diplomatic Conference on an international legal instrument(s) for the protection of genetic resources, traditional knowledge and traditional cultural expressions (TCEs).
L’OMPI sur la voie d’un instrument international pour la protection des ressources génétiques, des savoirs traditionnels et du folklore.
21.07.11
Eugenia Olliaro (KEI)
KEI comment on the Medicines Patent Pool license with Gilead
July 12, 2011
FYI: James Love (Tuesday: +44.785.543.6510, james.love@keionline.org). Thiru Balasubramaniam (thiru@keionline.org) or Krista Cox (krista.cox@keionline.org, +1.202.332.2670).
2 KEI/South Centre panel on Doha+10: The State of Implementation, 14 November 2011
Doha +10
On 14 November 2001, at its Ministerial in Doha, Qatar, the World Trade Organization (WTO) adopted the Doha Declaration on the TRIPS Agreement and public health. Exactly 10 years to the date, Knowledge Ecology International (KEI) and the South Centre have are co-hosting a side event at WIPO to discuss the following questions:
How have WTO members implemented paragraphs 4, 6 and 7 of the Doha Declaration? What changes are needed to achieve access to medicine for all?
Continue Reading